Yibo Shi, Hanzhang Wang, Borivoj Golijanin, Ali Amin, Joanne Lee, Mark Sikov, Elias Hyams, Gyan Pareek, Benedito A Carneiro, Anthony E Mega, Galina G Lagos, Lisha Wang, Zhiping Wang, Liang Cheng
Prostatic acinar adenocarcinoma accounts for approximately 95% of prostate cancer (CaP) cases. The remaining 5% of histologic subtypes of CaP are known to be more aggressive and have recently garnered substantial attention. These histologic subtypes - namely, prostatic ductal adenocarcinoma (PDA), intraductal carcinoma of the prostate (IDC-P), and cribriform carcinoma of the prostate (CC-P) - typically exhibit distinct growth characteristics, genomic features, and unique oncologic outcomes. For example, PTEN mutations, which cause uncontrolled cell growth, are frequently present in IDC-P and CC-P...
March 13, 2024: Urologic Oncology